It's often said that companies saved money on trips not taken during the pandemic — as though they had a choice — and didn't suffer much. But some outcomes show how not traveling can take a toll on operations, revenue generation and due diligence.

Travel restrictions "severely limited" a clinical trial for pharmaceutical company BrainStorm Cell Therapeutics. They mucked up the sales pipeline for metal coating firm AZZ Inc. They "slowed everything down" on M&A for fertility tech company Hamilton Thorne. Gold extractor Dakota Territory Resource Corp. had to delay a stock sale. The Dakota . . .

The full content is available to subscribers

Reminder: As per our Subscriber Agreement, reproduction or distribution of content and sharing user names and passwords are strictly prohibited.

Notify of